Back
 PP  Vol.13 No.7 , July 2022
Commentary: Unexpected Novel Chemical Weapon Agents Designed by Innocuous Drug-Development AI (Artificial Intelligence) Algorithm
Abstract: Recent publications reveal the disturbing information that a minor edit to an algorithm being used for designing legitimate drug candidates redirected the program in a way that resulted in the surprising design of novel chemical warfare agent candidates. Although this outcome was not the result of nefarious intent, and appropriate chemical defense authorities were notified, the potential implications of some misapplication of a drug-design algorithm for nefarious purposes are clear. This Commentary summarizes how otherwise benign Artificial Intelligence (AI) algorithms used for drug discovery can be easily reversed to design novel chemical warfare agents for which no effective antidote will be available, or perhaps even envisioned.
Cite this paper: Raffa, R. , Jr., J. , Miller, T. , Motto, D. , (2022) Commentary: Unexpected Novel Chemical Weapon Agents Designed by Innocuous Drug-Development AI (Artificial Intelligence) Algorithm. Pharmacology & Pharmacy, 13, 225-229. doi: 10.4236/pp.2022.137018.
References

[1]   Jiménez-Luna, J., Grisoni, F., Weskamp, N. and Schneider, G. (2021) Artificial Intelligence in Drug Discovery: Recent Advances and Future Perspectives. Expert Opinion on Drug Discovery, 16, 949-959.
https://doi.org/10.1080/17460441.2021.1909567

[2]   Vamathevan, J., et al. (2019) Applications of Machine Learning in Drug Discovery and Development. Nature Reviews Drug Discovery, 18, 463-477.
https://doi.org/10.1038/s41573-019-0024-5

[3]   Lavecchia, A. (2015) Machine-Learning Approaches in Drug Discovery: Methods and Applications. Drug Discovery Today, 20, 318-331.
https://doi.org/10.1016/j.drudis.2014.10.012

[4]   Lo, Y.C., Rensi, S.E., Torng, W. and Altman, R.B. (2018) Machine Learning in Chemoinformatics and Drug Discovery. Drug Discovery Today, 23, 1538-1546.
https://doi.org/10.1016/j.drudis.2018.05.010

[5]   Staszak, M., et al. (2022) Machine Learning in Drug Design: Use of Artificial Intelligence to Explore the Chemical Structure-Biological Activity Relationship. WIRES Computational Molecular Science, 12, e1568.
https://doi.org/10.1002/wcms.1568

[6]   Fleming, N. (2018) Computer-Calculated Compounds. Nature, 557, S55-S57.
https://doi.org/10.1038/d41586-018-05267-x

[7]   Savage, N. (2021) Tapping into the Drug Discovery Potential of AI. Nature Biopharma Dealmakers, June 2021, B37-B39.
https://doi.org/10.1038/d43747-021-00045-7

[8]   Paul, D., et al. (2021) Artificial Intelligence in Drug Discovery and Development. Drug Discovery Today, 26, 80-93. https://doi.org/10.1016/j.drudis.2020.10.010

[9]   Bender, A. and Cortés-Ciriano, I. (2021) Artificial Intelligence in Drug Discovery: What Is Realistic, What Are Illusions? Part 1: Ways to Make an Impact, and Why We Are Not There Yet. Drug Discovery Today, 26, 511-524.
https://doi.org/10.1016/j.drudis.2020.12.009

[10]   Elton, D.C., Boukouvalas, Z., Fuge, M.D. and Chung, P.W. (2019) Deep Learning for Molecular Design—A Review of the State of the Art. Molecular Systems Design & Engineering, 4, 828-849. https://doi.org/10.1039/C9ME00039A

[11]   Grisoni, F., et al. (2021) Combining Generative Artificial Intelligence and On-Chip Synthesis for de Novo Drug Design. Science Advances, 7, eabg3338.
https://doi.org/10.1126/sciadv.abg3338

[12]   Schneider, G. (2018) Automating Drug Discovery. Nature Reviews Drug Discovery, 17, 97-113. https://doi.org/10.1038/nrd.2017.232

[13]   King, R.D., et al. (2009) The Automation of Science. Science, 324, 85-89.
https://doi.org/10.1126/science.1165620

[14]   Saldivar-Gonzalez, F.I., Aldas-Bulos, V.D., Medina-Franco, J.L. and Plisson, F. (2022) Natural Product Drug Discovery in the Artificial Intelligence Era. Chemical Science, 13, 1526-1546. https://doi.org/10.1039/D1SC04471K

[15]   Urbina, F., Lentzos, F., Invernizzi, C. and Ekins, S. (2022) Dual Use of Artificial-Intelligence-Powered Drug Discovery. Nature Machine Intelligence, 4, 189-191.
https://doi.org/10.1038/s42256-022-00465-9

 
 
Top